Core Viewpoint - The stock of Meihao Medical (301363) has shown mixed performance with a slight increase in price, while the capital flow indicates a net outflow from major and retail investors, suggesting cautious sentiment in the market [1][2]. Financial Performance - As of the third quarter of 2025, Meihao Medical reported a total revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - The company's gross profit margin stands at 39.34%, with a net profit margin of 17.43%, indicating a relatively strong profitability compared to the industry average [3]. Market Position - Meihao Medical's total market capitalization is 13.397 billion yuan, which is above the industry average of 11.633 billion yuan, ranking 24th out of 124 companies in the medical device sector [3]. - The company's price-to-earnings ratio (P/E) is 48.26, which is lower than the industry average of 59.7, suggesting a potentially favorable valuation [3]. Capital Flow Analysis - On October 29, 2025, the stock experienced a net outflow of 9.5456 million yuan from major investors, accounting for 9.1% of the total trading volume, while retail investors saw a net inflow of 12.33% [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with significant outflows from major investors on several days, indicating volatility in investor sentiment [2]. Analyst Ratings - In the last 90 days, 17 institutions have rated Meihao Medical, with 15 buy ratings and 2 hold ratings, reflecting a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan, suggesting potential upside from the current trading price [4].
股票行情快报：美好医疗（301363）10月29日主力资金净卖出954.56万元